评估sPGA×BSA作为临床实践结局指标和治疗目标
本研究汇总三项ixekizumab治疗中重度银屑病3期试验(UNCOVER-1、-2、-3,N=3,866)数据,评估体表面积(BSA)及BSA与静态医师整体评估乘积(BSA×sPGA)作为PASI替代指标。BSA×sPGA与PASI的秩相关性在基线和第12周均强于BSA与PASI,第12周与PASI应答的一致率更高。作者认为BSA和BSA×sPGA可作为真实世界实践中PASI的可行替代工具,并可能适用于达标治疗策略。
要点
- BSA×sPGA与PASI的秩相关性在基线(r=0.759 vs r=0.707)和第12周(r=0.959 vs r=0.924)均强于BSA与PASI。
- 第12周与PASI 75应答的一致率:BSA×sPGA 93.8% vs BSA 86.2%;与PASI 90应答的一致率:BSA×sPGA 88.2% vs BSA 86.9%。
- ROC分析显示BSA和BSA×sPGA最准确的百分比变化分别为66%和83%(对应PASI 75切点)、84%和94%(对应PASI 90切点)。
核心结论
- BSA和BSA×sPGA是真实世界实践者用作PASI替代指标的可行工具,并可能适用于临床实践中的达标治疗策略。
研究设计与样本
- 汇总三项多中心、随机、双盲、安慰剂对照的ixekizumab治疗中重度银屑病3期试验(UNCOVER-1、-2、-3;N=3,866)数据。
主要发现
- BSA×sPGA与PASI的秩相关性在基线为r=0.759,BSA与PASI为r=0.707;第12周分别为r=0.959和r=0.924。
- 第12周与PASI 75应答的一致率:BSA为86.2%,BSA×sPGA为93.8%;与PASI 90应答的一致率:BSA为86.9%,BSA×sPGA为88.2%。
- PASI 75的阳性和阴性预测值BSA×sPGA均高于BSA;PASI 90的阳性预测值BSA×sPGA低于BSA,阴性预测值BSA×sPGA高于BSA。
- ROC曲线分析确定BSA和BSA×sPGA最准确的百分比变化分别为66%和83%(对应PASI 75切点)、84%和94%(对应PASI 90切点)。
关键数值与推荐
- BSA×sPGA与PASI的秩相关性:基线r=0.759,第12周r=0.959;BSA与PASI:基线r=0.707,第12周r=0.924。
- 第12周与PASI 75应答的一致率:BSA 86.2%,BSA×sPGA 93.8%。
- 第12周与PASI 90应答的一致率:BSA 86.9%,BSA×sPGA 88.2%。
- ROC分析:BSA和BSA×sPGA最准确的百分比变化分别为66%和83%(PASI 75切点)、84%和94%(PASI 90切点)。
临床怎么用
- 作者认为BSA和BSA×sPGA是真实世界实践者用作PASI替代指标的可行工具。
- 作者认为BSA和BSA×sPGA可能是临床实践中达标治疗策略适用的测量指标。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical outcome measures are becoming more important in psoriasis treatment. Reliable and standardized measures of severity feasible for clinical practice are needed. Our objective was to investigate body surface area (BSA) and the product of BSA and static Physician Global Assessment (sPGA) (ie, BSA × sPGA) as potential proxy measures for PASI scores. Data were pooled from three multicenter, randomized, double-blind, placebo-controlled, phase 3 trials of ixekizumab in patients with moderate to severe psoriasis (UNCOVER-1, -2, -3; N = 3,866). Assessments included the Psoriasis Area and Severity Index (PASI), BSA, and BSA × sPGA. Rank correlations between BSA × sPGA and PASI were stronger than between BSA and PASI (baseline, r = 0.759 vs. r = 0.707; week 12, r = 0.959 vs. r = 0.924). Week 12 concordance rates with PASI responses were as follows: for 75% reduction in PASI: BSA, 86.2%; BSA × sPGA, 93.8%; for 90% reduction in PASI: BSA, 86.9%; BSA × sPGA, 88.2%. The 75% reduction in PASI positive and negative predictive values were higher for BSA × sPGA versus BSA; for 90% reduction in PASI, positive predictive value was lower and negative predictive value was higher for BSA × sPGA versus BSA. Receiver operating characteristic curve analyses identified the most accurate percentage changes in BSA and BSA × sPGA as 66% and 83% for a 75% reduction in PASI cutoff and 84% and 94% for a 90% reduction in PASI, respectively. These results suggest that BSA and BSA × sPGA are viable tools for use as a PASI proxy by real-world practitioners and may be appropriate measurements for use in clinical practice for treat-to-target strategies.
引用
- Merola JF, Amato DA, See K, et al. Evaluation of sPGA × BSA as an Outcome Measure and Treatment Target for Clinical Practice. J Invest Dermatol. 2018. PMID: 29577919. doi:10.1016/j.jid.2018.01.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。